Stem Cell Therapy

World Market Report

MCP22862

EXECUTIVE ENGAGEMENTS

POOL

911
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

182
Interactions with Platform & by Email

PARTICIPANTS

36
Unique # Participated

VALIDATIONS

12
Responses Validated*

COMPANIES

12
Responses Validated*
* Login for a full stack data experience

DATE

OCT 2022

TABLES

22

PAGES

78

EDITION

6

PRICE

USD 5600

CODE

MCP22862


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

RANK

(S/A/N/T)

%

VALIDATED RESEARCH *

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2023?

» Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Stem Cell Therapy Market to Reach $605.2 Million by 2027
In the changed post COVID-19 business landscape, the global market for Stem Cell Therapy estimated at US$209 Million in the year 2020, is projected to reach a revised size of US$605.2 Million by 2027, growing at aCAGR of 16.4% over the period 2020-2027. Allogeneic, one of the segments analyzed in the report, is projected to record 16.9% CAGR and reach US$574.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Autologous segment is readjusted to a revised 9.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $61.1 Million, While China is Forecast to Grow at 15.7% CAGR
The Stem Cell Therapy market in the U.S. is estimated at US$61.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$104.7 Million by the year 2027 trailing a CAGR of 15.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.4% and 13.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.5% CAGR.

SELECT PLAYERS

Advanced Cell Technology; Anterogen, Ltd.; Biotime, Osiris Therapeutics; Cynata; Cytori Therapeutics; HolostemTerapieAvanzateS.r.l.; Human Longevity; JCR Pharmaceuticals; Medipost; Mesoblastand AlloSource; NuVasive; Osiris Therapeutics, Inc.; Pharmicell; Promethera Biosciences; RTI Surgical; Stemcell Technologies

SEGMENTS

» Type (Allogeneic, Autologous) » Cell Source (Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs, Other Cell Sources) » Application (Musculoskeletal Disorders, Wounds & Injuries, Cardiovascular Diseases, Gastrointestinal Diseases, Other Applications)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Stem Cell Therapy – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Stem Cell Therapy Market Analysis of Annual Sales in US$ for Years 2012 through 2027
World Recent Past, Current & Future Analysis for Placental / Umbilical Cord-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World Historic Review for Placental / Umbilical Cord-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Placental / Umbilical Cord-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
UNITED STATES
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
JAPAN
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
CHINA
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
EUROPE
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
FRANCE
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
GERMANY
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
UNITED KINGDOM
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2021 & 2027
Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2021 & 2027
Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2012, 2021 & 2027

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com